Introduction
Rheumatoid Arthritis (RA) is a chronic inflammatory and autoimmune disease characterized by the progressive destruction of the joints. RA is associated with increased morbidity and mortality. The disease is more frequent in women (3:1) and shows prevalence around of 0.5-1% in developed countries [1] . RA is a complex, polygenic and heterogeneous disease characterized by intricate interactions between genetic and environmental factors. The main genes related to susceptibility and severity of the disease are located in the major histocompatibility complex-HLA-region.
Specifically, the HLA-DRB1 alleles, encoding the so-called shared epitope (SE), can explain around 40% of the genetic burden of disease [2] . Other important genes related to susceptibility and/or severity of the disease are PTPN22, PADI4 and some loci related with the TNFα pathway [3, 4] .
The course and prognosis of RA has changed considerably since the advent of biologic
treatments. An early diagnosis and treatment along with tight control of the disease have improved the outcome of the disease. The mainstay of treatment for RA is currently based on two different therapeutic groups: conventional or synthetic disease-modifying antirheumatic drugs (DMARDs) and biological DMARDs, including TNF inhibitors (TNFi), monoclonal antibody directed against CD20 receptor of B cells (rituximab), IL-6 receptor antagonist (tocilizumab) and a specific neutralizer of the union between CD80/CD86 at antigen presenting cell and CD28 at T lymphocyte surface (abatacept).
In last years, a new generation of "targeted" DMARDs, i. 
Pharmacogenomics steps toward personalized medicine
Regrettably, the response to the therapy in RA is not uniform; rather, there is wide interindividual variability in the response. On the other hand, the possibility of side effect due to the therapy is not negligible. Furthermore, the high costs of these new therapies place a heavy burden on governments. Because of that, the search for tools that can help select the patients who are more appropriate for each specific therapeutic target is of major importance. In this regard, an objective to be reached in the near future is the personalized medicine by using biomarkers that can predict the response to treatment and avoid the possible occurrence of adverse effects (AEs) individually. This is especially true since at present 40-60% of patients with RA fail to achieve a satisfactory response to DMARDs, and around 15-30% can develop adverse drug events [5] .
Pharmacogenetics and pharmacogenomics hold a special interest in the search for possible accurate genetic markers that can predict the target and the response to a specific therapeutic target. Pharmacogenetics focuses on the study of genetic variations that determine the differential response to drugs as well as the prediction about the efficacy and occurrence of AEs with a specific drug in a particular an individual patient.
In this issue of the Journal, Tarnowski et al performed an exhaustive review of the literature on the most important genetic variants involved in the metabolism of synthetic and biological DMARDs [6] .
Despite the fact that genetic factor are of major importance in the response to the therapy, it is important to keep in mind that "non-genetic" factors, such as demographic and environmental factor as well as clinical or serologic markers can influence or predict the efficacy or toxicity of a drug in patients with RA, sometimes even better than the genetic biomarkers [7] . This is the case for the age, sex or smoking. For example, younger patients with RA tend to respond better to therapies and active smokers worse, possibly because they have higher levels of pro-inflammatory cytokines. Also, some parameters related to the disease itself, such as duration or activity and health assessment questionnaire (HAQ) at baseline may influence the response to therapy. In general, the higher basal activity or worse HAQ are the poorer is the response [7] .
Pharmacogenetics on conventional (synthetic) DMARDs
In their manuscript, Tarnowski et al review the main gene polymorphisms related to the efficacy or toxicity of methotrexate (MTX), leflunomide and sulfasalazine [6] . With respect to MTX, many genes are involved in its transportation into cells and out of them, its polyglutamation and the inhibition of the synthesis of purines, pyrimidines or DNA repair. Nevertheless, few are the genes in which polymorphisms show interest from a point of view of efficacy and toxicity [8, 9] . Firstly, it has been shown that the 80AA genotype of RFC-1 (also called SLC19A1) gene that carries MTX into the cell interior has been associated with a better response. Also, carriers of the 3435(C>T) T allele located in the exon 26 of the ABCB1 gene, which returns MTX outside of the cells, appear to have better response to MTX.
In contrast, RA patients carrying a triple repeat sequence in the homozygous form at the 5´-UTR end of the TYMS (thymidylate synthetase) gene (TSER*3/*3) need higher doses of drug to obtain the same effects, whereas six-base pair deletion in the 3´-UTR region individuals have a good response to conventional doses of MTX [10] . In the case of polymorphisms 677C/T and 1298A/C of the MTHFR gene, results related to efficacy or toxicity are not conclusive. Finally, the C>G polymorphism at the 347 position in the ATIC gene is associated with increased efficacy and toxicity [10] .
Regarding leflunomide, the most relevant enzymatic ways studied are the DHODH, a key enzyme of de novo pyrimidine synthesis, and the cytochrome pathway. As
Tarnowski et al pointed in their review [6] , it seems that individuals with RA carrying the 19AA genotype in the coding region of DHODH have lower rate of remission compared with those C allele carriers [10, 11] .
Results regarding several SNPs in the cytochrome pathway, especially in the CYP1A2, CYP2C19 and CYP3A4 genes, are inconclusive and appear to be more related to drug
toxicity. An interesting aspect related to the efficacy of leflunomide is the possible association between some polymorphisms at the estrogen receptor 1 (ESR1) and a better response to this drug in women [11] .
Sulfasalazine (SASP) is another drug commonly used in low-grade RA. SASP is converted into 5-ASA and sulfapyridine, and later it is metabolized in the liver through acetylation by N-acetyltransferases (NAT1, NAT2). Slow acetylators due to polymorphisms in these genes, especially in NAT2, are at increased risk of developing toxicity. The prevalence of slow acetylators varies greatly between races; 20% in Asiatic individuals and 60% in Africans or Caucasian. Yet, common doses of SASP seem to be more effective in patients with RA who are slow acetylators [10] .
Overall, the study of SNPs in genes involved in the metabolism of conventional (synthetic) DMARDs seems to be more useful in detecting patients susceptible to develop toxicity, since these drugs induce a high rate of AEs. 
Pharmacogenetics of biologic DMARDs
Unlike conventional DMARDS, biologic DMARDS are high-cost drugs and, due to this, studies on these new agents are focused on the search of good responders.
Unfortunately, although this is an exciting issue, there are few polymorphisms that so far have shown a significant participation in the prediction of the efficacy or safety of these drugs in clinical practice.
TNF inhibitors (TNFi)
Regarding TNFα antagonists, most studies were conducted on small numbers of patients with controversial results. The most interesting data seem to be related to some SNPs located at -238, -308 and -857 positions in TNF promoter region with questionable results. In this regard, although some studies found that -308GG genotype was associated with a good response to TNFi, especially to etanercept; two recent metaanalyses concluded that the -308G/A polymorphism of TNF is not a good predictor of clinical response to TNFi [12, 13] . By contrast, a sensitivity analysis revealed a possible association between response to infliximab and the TNF -238A/G polymorphism [12] .
Other studies have demonstrated association between clinical response and some polymorphisms in TNFα receptor genes.
A meta-analysis involving more than 2 million common variants in 2706 RA patients disclosed a positive association between CD84 expression and response to etanercept.
Other genes that have been associated with satisfactory and consistent results in terms of response to various anti-TNF agents are NLRP3/CARD8 (encoding NLRP3-inflammasome), PTPRC, PDE3A, NF-kB and CHUK [14, 15] . In contrast, no association has been detected with other important genes involved in RA pathogenesis such as the IL-6 receptor gene, HLA-DRB1 shared epitope, PTPN22 or TGFb [7] . A summary of the main genes and polymorphisms implicated in the efficacy and safety of biologic DMARDs is shown in Table 2 .
Other biologic DMARDs
Experience with the use of other biologics is more limited. In the case of tocilizumab, it appears that some variants in the gene of IL-6 receptor, located in exon 9 and introns 1 and 9, could be associated with a poorer clinical response when the AAC haplotype is expressed.
Regarding rituximab, the available information is quite poor. Nevertheless, some polymorphisms located in the IL-6 (174G/C), TGFB1, FCG3A and promoter region of BAFF genes suggest promising results. Table 2 shows a more detailed information on the main genes related to response to biologic DMARDs.
Conclusions
Pharmacogenetics is a discipline that can provide important solutions to the problems related to the management of chronic and complex diseases such as RA. This is especially true for drugs that have a high rate of AEs (conventional DMARDs) or a high cost (biological DMARDs), where besides safety and efficacy criteria, costeffectiveness criteria should also be kept in mind. Pharmacogenetics and related disciplines can yield answer to many of these issues, although there are still many questions to be elucidated.
Expert Opinion
At present, we are still far from being able to apply the concepts known on the pharmacogenetics of DMARDs into clinical practice. This can be due to several reasons. First, RA is a polygenic, heterogeneous and complex disease, in which many of Taken together, we conclude that the use of pharmacogenetics in clinical practice in patients with RA is currently limited. Results derived from genome-wide association studies (GWAS) conducted in homogeneous and well characterized populations will allow us to obtain more reliable information. Also, the introduction of more powerful and complementary techniques based on pharmacogenomics, proteomics and transcriptomics will provide useful information to design individual therapeutic management. This is probably the only way towards personalized health care, focused on the search for greater efficiency and safety, with fewer side effects and a more cost effective approach for each patient. 
